Corporate News
Ad-hoc: Biosilu Healthcare AG - Main shareholder signals to exercise his subscription right
The main shareholder signals to exercise his subscription right.Read MoreAd-hoc: Biosilu Healthcare AG adjusts company’s business model
Frankfurt am Main, January 2nd, 2018 – the management of Biosilu Healthcare AG, Frankfurt am Main, (ISIN DE000A0SMU87, WKN A0SMU8) has adjusted the company‘s business model.Read MoreDD - Biosilu Healthcare AG: Notification of transactions of directors
Biosilu Healthcare AG: Notification of transactions of directors.Read MoreAd-hoc: Biosilu Healthcare AG beschließt Barkapitalerhöhung
Biosilu Healthcare AG beschließt Barkapitalerhöhung aus genehmigtem Kapital mit Privatplatzierung.
Read MoreAd-hoc: Biosilu Healthcare AG: Vorstand und Aufsichtsrat schlagen Kapitalerhöhung vor
Vorstand und Aufsichtsrat der Biosilu Healthcare AG schlagen Kapitalerhöhung vor.Read MoreAd-hoc: Biosilu Healthcare AG:Change in the Management Board
Biosilu Healthcare AG today announced that Mathis Schultz will lead the firm as the new CEO from November 23, 2017.
Frankfurt, September 18, 2017 - The life science company Biosilu Healthcare AG (ISIN DE000A0SMU87), listed on the Munich Stock Exchange, announced today the signing of a term sheet defining the framework of a future license and collaboration agreement between Biosilu Healthcare and Glycotope, a biopharmaceutical company based in Berlin. The framework agreement comprises China including Hong Kong and Macau. Financial details have not been disclosed.
Read MoreBiosilu's new corporate presentation available
The new corporate presentation of Biosilue Healthcare is available for download.
Read MoreDD - Biosilu Healthcare AG: Notification of transactions of Directors
Biosilu Healthcare AG: Notification of transactions of directors.
Read MoreAd-hoc: Biosilu Healthcare AG: Annual report 2016
The Biosilu Healthcare AG publishes its annual report 2016, which has been approved by the supervisory board today.
Read MoreAd-hoc: Biosilu Healthcare AG: capital increase by up to 8.7% fully subscribed
The Biosilu Healthcare AG fully subscribed a capital increase by up to 8.7% at a placement price of EUR 2.78 per share. The gross issuance volume is EUR 500,400.00.
Read MoreAd-hoc: Biosilu Healthcare AG resolves capital increase
The Biosilu Healthcare AG resolves a capital increase by up to 8.7% from authorized capital to increase share capital by issuing up to 180,000 new shares.
Read Moreamp biosimilars AG (Biosilu Healthcare AG) extraordinary general meeting
Frankfurt am Main, May 9, 2017 – amp biosimilars AG (ISIN: DE000A0SMU87, WKN A0SMU8), listed on Munich Stock Exchange’s Open Market, held its extraordinary general meeting on May 8, in Berlin with 72.43 percent of the share capital represented. All management proposals were accepted unanimously.
Read Moreamp biosimilars AG successfully completes cash capital increase
Frankfurt am Main, April 3, 2017 – amp biosimilars AG, Frankfurt am Main, (ISIN DE000A0SMU87, WKN A0SMU8) has successfully completed its share capital increase resolved today, with approval of the supervisory board, from EUR 2,050,000.00 to EUR 2,075,000.00 by issuing 25,000 new no-par value bearer shares against cash contribution partially utilizing the existing authorized capital and excluding the shareholders’ subscription rights.
Read MoreAd-hoc: amp biosimilars AG adjusts company’s business model
Frankfurt am Main, March 30, 2017 – the management of amp biosimilars AG, Frankfurt am Main, (ISIN DE000A0SMU87, WKN A0SMU8) has adjusted the company‘s business model.
Read MoreAd-hoc: amp biosimilars AG: Dr Stefan Elßer appointed to the Supervisory Board
On March 14, 2017, Dr Stefan Elßer has appointed by the court of Frankfurt am Main to the Supervisory Board of amp biosimilars AG. Dr Elßer replaces Dr Thomas Zimmer whose term of office ended by the end of the annual general meeting 2016.
Read Moreamp biosimilars AG schließt den planmäßigen Umbau des Managements ab.
Öffnen Sie die PDF-Datei hier.
Read MoreOrdentliche Hauptversammlung der amp biosimilars AG
Öffnen Sie die PDF-Datei hier.
Read MoreÖffnen Sie die PDF-Datei hier.
Read MoreAd-hoc: Änderungen im Vorstand
Öffnen Sie die PDF-Datei hier.
Read Moreamp biosimilars announces Klaus K. Wilgenbus as new CEO
amp biosimilars AG (ISIN: DE000A0SMU87) today announced that Klaus K. Wilgenbus will lead the firm as the new CEO from July 1, 2016.
Click the link to download the pdf.
Read More